
Relay Therapeutics will present data at a medical meeting Friday that give investors and oncologists the first look at RLY-4008, its drug to treat a form of liver cancer.
“So far in the clinic, 4008 has done everything we designed it to do from the outset,” Don Bergstrom, Relay’s chief medical officer, told STAT.
Create a display name to comment
This name will appear with your comment